Vincenzo P.
- Country
- Italy
- Department
- UO di Nefrologia,Trapianti e Dialisi
Research Overview
- Evaluation of Corticosteroids, Dapagliflozin, and RASBs on Proteinuria in IgA Nephropathy Patients with Active and Chronic Renal Lesions
- Evaluation of Zibotentan and Dapagliflozin Combination Versus Dapagliflozin Monotherapy in Chronic Kidney Disease with High Proteinuria: A Phase III Randomized Study
- Efficacy and Safety of Efepoetin Alfa Versus Darbepoetin Alfa in Anemia Management for Chronic Kidney Disease Patients on Dialysis: A Phase III Randomized Study
Data & Insights
Has run more than one trial at 107 of 434 partner sites.
Specializations
Kidney Disease Management
The investigator specializes in treating various forms of chronic kidney disease (CKD), with particular emphasis on managing patients with high proteinuria and IgA nephropathy (IgAN).
- Progressive kidney disorders
- Targeted therapy approaches
- Proteinuria management
Their research extends to innovative therapeutic combinations for improving kidney function outcomes.
Dialysis and ESKD Care
The investigator focuses on treating patients with end-stage kidney disease (ESKD) and associated complications, including cardiovascular disease in dialysis patients.
- Maintenance dialysis therapy
- Cardiovascular complications
- Inflammatory markers management
Their work includes exploring new therapeutic approaches for dialysis patients with concurrent conditions.
Renal Anemia Treatment
The investigator has developed expertise in managing anemia in chronic kidney disease, particularly in patients undergoing dialysis treatment.
- Hemoglobin level management
- Comparative treatment approaches
- Erythropoiesis-stimulating agents
Their research includes evaluation of various therapeutic agents for optimal anemia control in CKD patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.